Fund moves

Jazz Pharmaceuticals (JAZZ): Frontier Capital Management Co LLC reduced its stake -240K shares

Frontier Capital Management Co LLC reduced its stake in Jazz Pharmaceuticals, per its Q2 2026 13F.

277K
Shares reported · -240K vs prior quarter
0.62%
Disclosed portfolio weight
$66.8M
Reported value
Holdings as of
Jun 30, 2026
Filed
Aug 14, 2026

What stands out in this filing

  • 517,284 shares in Q1 2026, 277,279 now (−46.4% in share count).
  • Reported at $66.8M, 0.62% of the portfolio value in this 13F filing.
  • 22 other tracked managers reported the same kind of change for Q2 2026.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: signed an important agreement, 4 days earlier (Aug 10, 2026). The first one after it: signed an important agreement, 12 days later (Aug 26, 2026).

  1. InsiderDirector sold ~$267K of JAZZ shares in the open market
  2. InsiderDirector sold ~$1.44M of JAZZ shares in the open market
  3. Company filing · Form 8-K · ResultsReported its results
  4. InsiderDirector sold ~$1.52M of JAZZ shares in the open market
  5. Company filing · Form 8-K · Material agreementSigned an important agreement

What came next

  1. Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  2. Insider · 1 personInsiders: 6 sales (~$19.2M)
  3. InsiderDirector sold ~$1.5M of JAZZ shares in the open market
  4. InsiderCEO sold ~$486K of JAZZ shares in the open market
  5. InsiderOfficer sold ~$289K of JAZZ shares in the open market
  6. Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  7. InsiderDirector sold ~$1.38M of JAZZ shares in the open market
  8. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.”
  9. InsiderCEO sold ~$473K of JAZZ shares in the open market
  10. Company filing · Form 8-K · ResultsReported its results
  11. Company filing · Form 8-K · ResultsReported its results
  12. InsiderDirector sold ~$1.3M of JAZZ shares in the open market
  13. InsiderCEO sold ~$225K of JAZZ shares in the open market
  14. Insider · 1 personInsiders: 2 sales (~$327K)
  15. 5% stakeFMR LLC reported a passive stake (13G) of 8.6%
  16. Insider · 1 personInsiders: 4 sales (~$16.2M)
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Jazz Pharmaceuticals

For Jazz Pharmaceuticals, OQRO holds 25 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JAZZ page.

How this filing works

Explore the data

Common questions

What does this filing report about Jazz Pharmaceuticals (JAZZ) stock?

Frontier Capital Management Co LLC reduced its stake in Jazz Pharmaceuticals, per its Q2 2026 13F. Now 277K shares, $66.8M reported value, 0.62% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Jun 30, 2026. Filed: Aug 14, 2026.

What stands out in this filing?

517,284 shares in Q1 2026, 277,279 now (−46.4% in share count). Reported at $66.8M, 0.62% of the portfolio value in this 13F filing. 22 other tracked managers reported the same kind of change for Q2 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Jazz Pharmaceuticals recently?

For Jazz Pharmaceuticals, OQRO holds 25 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the JAZZ page.

Does this mean JAZZ stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Jazz Pharmaceuticals

Everything OQRO holds on this company is on its JAZZ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data